Navigation Links
New Report Provides Expert Analysis of Recent Advances and Setbacks in Parkinson's Disease Drug Development
Date:12/2/2008

SCOTTSDALE, Ariz., Dec. 2 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for pharma and biotech companies with a stake in the market for Parkinson's disease (PD) therapies. This report, entitled Thought Leader Insight & Analysis -- Parkinson's Disease, is based on 9 interviews conducted with PD experts from the US (6) and Europe (3).

"Regardless of whether they're delivered via surgical implants, gene therapies, viral vectors or old-fashioned small molecules, the most dramatic advances in Parkinson's disease therapeutics will be used in early stage disease to prevent loss of functional status and quality of life," says lead author Dr. Jeffrey D. Berk. "Improvements in invasive procedures and new understanding of the pathophysiology of Parkinson's disease are shifting the risk/benefit ratio and opening up new possibilities for patients."

In addition to discussing today's treatment goals, available therapeutic approaches and unmet needs, MedPredict's expert panel explores the current state of the art in new approaches being developed for the symptomatic treatment and disease modification of PD, including:

    -- Unmet needs: dopamine agonists, wearing off vs. dyskinesia, depression,
       pain, dementia, psychosis, neuroprotection, impulse control (punding),
       restless legs syndrome;
    -- Deep brain stimulation (risk/benefit, pharmacoeconomics);
    -- Gene therapies and growth factors (human fetal implants, GDNF,
       neurturin, neublastin, GAD/glutamic acid decarboxylase),
       alpha-synuclein;
    -- Dopamine agonists, monoamine oxidase inhibitors;
    -- Levodopa formulations, COMT inhibitors; and
    -- Adenosine A2A receptor antagonists, cholinesterase inhibitors, AMPA,
       5-HT, anticonvulsants, antihypertensives, farnesyl transferase
       inhibitors.

Companies mentioned in this report include: Acadia, Amersham Pharmacia Biotech/GE Healthcare, Amsterdam Molecular Therapeutics, Bayer-Schering, Bayer-Schering/Titan, Boehringer Ingelheim, Ceregene/Genzyme, Eisai, Elan, Forest, GlaxoSmithKline, GSK/XenoPort/Astellas, Ipsen, Kyowa, Lilly, Link Medicine Corp, Medtronic, Merck-Serono, Merck-Serono/Newron, NeuroDerm, Neurologix, Novartis, NsGene, Ortho-McNeill-Janssen, Pfizer, Qrx Pharma, Schering-Plough, Solvay, Solvay/Wyeth, Teva, UCB, Valeant, and Wyeth.

This report can be purchased by contacting MedPredict (http://www.medpredict.com).

About MedPredict

MedPredict maintains a proprietary database of over 1,000 global physician thought leaders, including 40+ specialties in 30+ therapeutic categories. Based on primary interviews with these thought leaders, MedPredict publishes periodic reports in each category to keep clients up-to-date on emerging trends and competitive activity. The reports include thought leader reactions to recent publications and medical conferences, as well as clinical, regulatory and marketing activity.


'/>"/>
SOURCE MedPredict
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. PharmSource and BioProcess Technology Consultants Announce Publication of New Market Report: Cell Culture Manufacturing Capacity: Trends and Outlook through 2013
2. European Nephrologists Share Insights on the Management of Renal Anemia and Hyperphosphatemia in Latest BioTrends Report
3. The Female Health Company Reports Record Results for Fiscal Year 2008, at High End of Guidance
4. Encorium Reports Third Quarter 2008 Financial Results
5. Interim Report for the Period 1 January - 30 September 2008 (Unaudited)
6. NSD Bio Group, LLC chosen by U.S.-China Economic & Security Review Commission for Report on Chinas High Tech Sectors
7. Duska Therapeutics Provides Program Update and Reports Third Quarter 2008 Financial Results
8. SPO Medical Reports Nine Month Period Ending September 2008
9. Sinovac Reports Third Quarter 2008 Unaudited Financial Results
10. Benda Pharmaceutical Reports Third Quarter 2008 Financial Results
11. Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... ... July 25, 2017 , ... ... to announce that its regenerative stem cell therapy has been used on more ... successful treatment for horses with potentially fatal injuries to tendons and ligaments. , ...
(Date:7/26/2017)... FL (PRWEB) , ... July 26, 2017 , ... ... learning algorithms targeted towards leveraging the years of diagnostic excellence by Mayo Clinic ... The first product suite will be distributed through the Microsoft Azure platform ...
(Date:7/25/2017)... (PRWEB) , ... July 25, 2017 , ... Fiberstar, ... food and beverage industry, offers Citri-Fi® 125. This natural citrus fiber is used to ... and extend real tomato in sauces, condiments and spreads. Today, more than ever, consumers ...
(Date:7/24/2017)... 2017 Intralytix, Inc. announced that it received ... French family group. This investment marks the beginning of ... commercialize bacteriophage-based products, for various benefits in human health ... As a global key ... markets innovative solutions for baking, food taste & pleasure, ...
Breaking Biology Technology:
(Date:3/24/2017)... DUBLIN , Mar 24, 2017 Research ... Vehicle Access System Market Analysis & Trends - Industry Forecast to ... ... poised to grow at a CAGR of around 15.1% over the ... This industry report analyzes the market estimates and forecasts for ...
(Date:3/22/2017)... 21, 2017   Neurotechnology , a provider ... today announced the release of the SentiVeillance ... improved facial recognition using up to 10 surveillance, ... computer. The new version uses deep neural-network-based facial ... it utilizes a Graphing Processing Unit (GPU) for ...
(Date:3/20/2017)... March 20, 2017 At this year,s CeBIT Chancellor ... biometrics manufacturer DERMALOG. The Chancellor came to the DERMALOG stand together with ... this year,s CeBIT partner country. At the largest German biometrics company the ... fingerprint, face and iris recognition as well as DERMALOGĀ“s multi-biometrics system.   ... ...
Breaking Biology News(10 mins):